

**Review of over 15 years post-marketing safety surveillance spontaneous data for the human rotavirus vaccine (*Rotarix*) on intussusception**

**Journal:** Drug Safety

**Authorship:** Tina Singh<sup>1</sup>, Frédérique Delannois<sup>1</sup>, François Haguinet<sup>1</sup>, Lifeter Yenwo Molo<sup>1</sup>

**Affiliations:**

<sup>1</sup>GSK, Avenue Fleming 20, 1300 Wavre, Belgium

**Corresponding author:**

Tina Singh

[tina.x.singh@gsk.com](mailto:tina.x.singh@gsk.com)

**Electronic supplementary material 3** Overview of the duration between intussusception (IS) onset and treatment initiation as well as surgical management of confirmed IS cases with a time to onset of  $\leq 30$  days requiring  $>4$  days of hospitalisation

